Therapeutic evaluation of a microbioartificial liver with recombinant HepG2 cells for rats with hepatic failure

Bibliography

• Nyberg SL, Hibbs JR, Hardin JA, et al. Influence of human fulminant hepatic failure sera on endogenous retroviral expression in pig hepatocytes. Liver Transpl 2000;6(1):76-84
   PubMed Web of Science ®Google Scholar
• Frühauf JH, Mertsching H, Giri S, et al. Porcine endogenous retrovirus released by a bioartificial liver infects primary human cells. Liver Int 2009;29(10):1553-61
   PubMed Web of Science ®Google Scholar
• Kinasiewicz A, Gautier A, Lewinska D, et al. Culture of C3A cells in alginate beads for fluidized bed bioartificial liver. Transplant Proc 2007;39(9):2911-3
   PubMed Web of Science ®Google Scholar
• Filippi C, Keatch SA, Rangar D, et al. Improvement of C3A cell metabolism for usage in bioartificial liver support systems. J Hepatol 2004;41(4):599-605
   PubMed Web of Science ®Google Scholar
• Giri S, Bader A. Improved preclinical safety assessment using micro-BAL devices: the potential impact on human discovery and drug attrition. Drug Discov Today 2011;16(9-10):382-97
   PubMed Web of Science ®Google Scholar
• Parekkadan B, van Poll D, Suganuma K, et al. Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS One 2007;2(9):e941
   PubMed Web of Science ®Google Scholar
• Shinoda M, Tilles AW, Kobayashi N, et al. A bioartificial liver device secreting interleukin-1 receptor antagonist for the treatment of hepatic failure in rats. J Surg Res 2007;137(1):130-40
   PubMed Web of Science ®Google Scholar
• Omasa T, Kim K, Hiramatsu S, et al. Construction and evaluation of drug-metabolizing cell line for bioartificial liver support system. Biotechnol Prog 2005;21(1):161-7
   PubMed Web of Science ®Google Scholar
• Enosawa S, Miyashita T, Saito T, et al. The significant improvement of survival times and pathological parameters by bioartificial liver with recombinant HepG2 in porcine liver failure model. Cell Transplant 2006;15(10):873-80
   PubMed Web of Science ®Google Scholar
• Tang NH, Wang XQ, Li XJ, et al. Ammonia metabolism capacity of HepG2 cells with high expression of human glutamine synthetase. Hepatobiliary Pancreat Dis Int 2008;7(6):621-7
   PubMed Web of Science ®Google Scholar
• Mavri-Damelin D, Eaton S, Damelin LH, et al. Ornithine transcarbamylase and arginase I deficiency are responsible for diminished urea cycle function in the human hepatoblastoma cell line HepG2. Int J Biochem Cell Biol 2007;39(3):555-64
   PubMedGoogle Scholar
• Tang N, Wang Y, Wang X, et al. Stable overexpression of arginase I and ornithine transcarbamylase in HepG2 cells improves its ammonia detoxification. J Cell Biochem 2012;113(2):518-27
   PubMed Web of Science ®Google Scholar
• Wang L, Sun J, Li L, et al. Comparison of porcine hepatocytes with human hepatoma (C3A) cells for use in a bioartificial liver support system. Cell Transplant 1998;7(5):459-68
   PubMed Web of Science ®Google Scholar
• Mavri-Damelin D, Damelin LH, Eaton S, et al. Cells for bioartificial liver devices: the human hepatoma-derived cell line C3A produces urea but does not detoxify ammonia. Biotechnol Bioeng 2008;99(3):644-51
   PubMed Web of Science ®Google Scholar
• Millis JM, Cronin DC, Johnson R, et al. Initial experience with the modified extracorporeal liver-assist device for patients with fulminant hepatic failure: system modifications and clinical impact. Transplantation 2002;74(12):1735-46
   PubMed Web of Science ®Google Scholar
• Harimoto N, Taketomi A, Kitagawa D, et al. The newly established human hepatocyte cell line: application for the bioartificial liver. J Hepatol 2005;42(4):557-64
   PubMed Web of Science ®Google Scholar
• Nibourg GA, Huisman MT, van der Hoeven TV, et al. Stable overexpression of pregnane X receptor in HepG2 cells increases its potential for bioartificial liver application. Liver Transpl 2010;16(9):1075-85
   PubMed Web of Science ®Google Scholar
• Dejong CH, Deutz NE, Soeters PB. Ammonia and glutamine metabolism during liver insufficiency: the role of kidney and brain in interorgan nitrogen exchange. Scand J Gastroenterol Suppl 1996;218:61-77
   PubMedGoogle Scholar
• Scaglia F, Carter S, O'Brien WE, et al. Effect of alternative pathway therapy on branched chain amino acid metabolism in urea cycle disorder patients. Mol Genet Metab 2004;81(Suppl 1):S79-85
   PubMed Web of Science ®Google Scholar
• Enosawa S, Miyashita T, Suzuki S, et al. Long-term culture of glutamine synthetase-transfected HepG2 cells in circulatory flow bioreactor for development of a bioartificial liver. Cell Transplant 2000;9(5):711-5
   PubMed Web of Science ®Google Scholar
• Miyashita T, Enosawa S, Suzuki S, et al. Development of a bioartificial liver with glutamine synthetase-transduced recombinant human hepatoblastoma cell line, HepG2. Transplant Proc 2000;32(7):2355-8
   PubMed Web of Science ®Google Scholar